Skip to main content

Diffuse Large B-Cell Lymphoma

Featured Article
According to study findings, neurologic toxicities from treatment for relapsed or refractory diffuse large B-cell lymphoma increased total health care costs more than $70,000 on average for US…
Per-patient-per-year costs for DLBCL in the United States are considerable, with many patients requiring treatment beyond their first line of therapy, according to a real-world study.

Interactive Features

True or False: Skipping radiation and receiving less chemotherapy may become the new standard of care.
Back to Top